Discovery and Identification of Novel 5-Hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-one Derivatives as Potent β<sub>2</sub>-Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation
作者:Gang Xing、Zhenli Li、Zhengxing Zhi、Ce Yi、Ruiwen Zhang、Huali Yang、Yuyang Zhang、Bin Lin、Yang Liu、Li Pan、Maosheng Cheng
DOI:10.1021/acs.jmedchem.3c02074
日期:2024.2.22
optimizing β2-agonistic activity and selectivity remains essential for achieving favorable therapeutic outcomes. A structure-based molecular design workflow was employed to discover a novel class of β2 agonists featuring a 5-hydroxy-4H-benzo[1,4]oxazin-3-one scaffold, which potently stimulated β2 adrenoceptors (β2-ARs). Screening for the β2-agonistic activity and selectivity led to the identification of
尽管β 2 受体激动剂对于治疗慢性呼吸系统疾病至关重要,但优化β 2 受体激动剂的活性和选择性对于获得良好的治疗结果仍然至关重要。采用基于结构的分子设计工作流程来发现一类新型的 β2 激动剂,其特点是 5-羟基-4H-苯并[1,4]恶氮嗪-3-酮支架,可有效刺激β 2 个肾上腺素能受体 (β2-ARs)。筛选 β2-激动活性和选择性导致鉴定出化合物 A19 (EC50 = 3.7 pM),该化合物在含有内源性 β2-AR 的 HEK-293 细胞中起部分 β2-激动剂的作用。化合物 A19 对离体豚鼠气管条表现出显着的松弛作用、快速起效时间 (Ot50 = 2.14 min) 和长作用持续时间 (>12 h),以及有利的体内药代动力学特性,使 A19 适合吸入给药。此外,A19 抑制了 COPD 大鼠模型中炎性细胞因子和白细胞的上调,并改善了肺功能,从而表明 A19 是进一步研究的潜在 β2